

SPEAKERS

EXTERNAL SPEAKERS

- Prof. Dr. Federica Cavallo
Università di Torino
- Prof. Dr. Sylvain Choquet
Hôpital Pitié-Salpêtrière, Paris
- Prof. Dr. Jörg Henes
Universitätsklinikum Tübingen
- Prof. Dr. Christoph Stein-Thoeringer
Universitätsklinikum Tübingen
- Prof. Dr. Daniel Nowak
Paul-Ehrlich-Institut
- Prof. Dr. Robert Zeiser
Universitätsklinikum Freiburg

INTERNAL SPEAKERS

- Medizinische Klinik V (Hämatologie, Onkologie und Rheumatologie), *Universitätsklinikum Heidelberg*
- Prof. Dr. Antje Blank
- Prof. Dr. Peter Dreger
- Dr. Kiavasch Farid
- Prof. Dr. Anthony D. Ho
- PD Dr. Tobias Kessler
- Prof. Dr. Dr. Thomas Luft
- Prof. Dr. Carsten Müller-Tidow
- Prof. Dr. Marc Raab
- Dr. Tim Sauer
- Prof. Dr. Anita Schmitt
- Prof. Dr. Michael Schmitt
- Prof. Dr. Stefan Schönland
- PD Dr. Maria-Luisa Schubert
- Prof. Dr. Guy Ungerechts

SPONSORS

Gilead Sciences GmbH	€ 22.000
Johnson & Johnson	€ 22.000
Pierre Fabre Pharma GmbH	€ 20.000
Medac Gesellschaft für klinische Spezialpräparate m.b.H.	€ 5.000
AbbVie Deutschland GmbH & Co. KG	€ 3.000
Miltenyi Biotec B.V. & Co. KG	€ 2.000
Roche Pharma AG	€ 2.000
Servier Deutschland GmbH	€ 2.000
Mallinckrodt Pharmaceuticals Therakos (UK) Ltd.	€ 1.000
MSD Sharp & Dohme GmbH	€ 1.000
Takeda Pharma Vertrieb GmbH & Co. KG	€ 1.000
Lilly Deutschland GmbH	€ 1.000
Terumo Blood and Cell Technologies	€ 1.000

VENUE

Heidelberg University Hospital
Medical Clinic, Grand Auditorium
Im Neuenheimer Feld 410
69120 Heidelberg

CONTACT

Enquiries of an organizational nature may be directed to

Marcel Pichal, M.A.
Phone: 06221 56-7989
E-Mail: marcel.pichal@med.uni-heidelberg.de

Executive assistant to Prof. Michael Schmitt
Universitätsklinikum Heidelberg
Medizinische Klinik V | Zelluläre Immuntherapie
Im Neuenheimer Feld 410 | 69120 Heidelberg

REGISTER

To safeguard a proper organization of this conference, we ask participants to register through the following portal by 15 October 2025 — at the latest.

JOIN US HERE:
WWW.UKHD.DE/CELLTHERAPYSYMPOSIUM

Should you encounter any issues in the course of your formal registration, please get in touch with

Josefine Berger, M.Sc.:
Phone: 06221 56-8264
E-Mail: lena.berger@med.uni-heidelberg.de



HEIDELBERG
UNIVERSITY
HOSPITAL



9th CELL-THERAPY SYMPOSIUM

NOVEMBER 7 & 8, 2025

Medical Clinic, Grand Auditorium
Im Neuenheimer Feld 410
69120 Heidelberg

Department of Internal Medicine V
(Hematology, Oncology and Rheumatology)



DEAR COLLEAGUES,

A year has passed since the last *Cell-Therapy Symposium* took place. Within this brief period of time, tremendous progress has been made at our clinic with view to CAR T-cell therapy: More than 350 patients have received this leading-edge treatment at our medical center.

Across the globe, more than 50,000 patients have undergone remarkably successful treatment regimens for acute leukemia, Non-Hodgin’s lymphoma, as well as for myeloma. In light of this substantial track record, current therapeutic algorithms applied to tackle these diseases need to be revisited.

This symposium is meant to put special emphasis on an in-depth comparison of bispecific antibodies and CAR-T cells; in conjunction with a survey of novel TCR-T-cell therapies directed at solid tumors.

Both the ongoing exploration and identification of novel targets, as well as the preclinical research necessary to further the development of immunogenic therapies will be overarching themes of our scientific discussion.

We are looking forward to welcoming you to our symposium.

With very warm regards from Heidelberg



Michael Schmitt Carsten Müller-Tidow Peter Dreger

The participation is free of charge.

This conference is certified by the
Landesärztekammer Baden-Württemberg.

Corresponding CME-credits are granted.

PROGRAM

FRIDAY, NOVEMBER 7, 2025
SCIENTIFIC SYMPOSIUM — PART 1

13:00 Registration, lunch and beverages
Get-together

13:30 Welcome address
C. Müller-Tidow

PLASMA-CELL DISEASES

Chairs: M. Schmitt / A.D. Ho

13:40 Immune and Cell Therapy for
Multiple Myeloma
M. Raab

14:00 CAR T-Cell Therapy for Patients with
Amyloidosis
S. Schönland

14:20 The Role of Mesenchymal Stromal-
Cells (MSCs) in the Treatment of
Graft-versus-Host Disease (GvHD)
R. Zeiser

15:00 - 16:30 Extended coffee break
with the option to attend a satellite
symposium by Johnson & Johnson

16:30 Coffee break

HOME-BREWN CARTs

Chairs: P. Dreger / M.-L. Schubert

17:00 CAR T-Cell Products — A Regulatory
Perspective
D. Nowak

17:30 Hospital Exemption for CAR
Products in Germany
M. Schmitt

EBV-SPECIFIC T-CELLS

T. Luft / T. Sauer

18:00 Treatment of EBV-Driven Diseases
through EBV-Specific T-Cells
K. Farid

18:30 Real-World Data for Tabelecleucel
in France
S. Choquet

19:00 Experience with Tabelecleucel
in Italy
F. Cavallo

19:30 Closing Remarks

SATURDAY, NOVEMBER 8, 2025
SCIENTIFIC SYMPOSIUM — PART 2

08:30 Registration
Get-together

MAKING CARs BETTER

Chairs: A. Schmitt / T. Luft

09:00 Extracorporeal Photopheresis
Therapy (ECP) for GvHD Preserves
GvL, Anti-Viral Effects, and CAR
T-Cell Function
A. Schmitt

09:20 Optimizing CAR T-Cell Therapy
in AML
C. Müller-Tidow

09:50 CAR T-Cell Therapies for Solid
Tumors
G. Ungerechts

10:10 CD318.CAR T-Cells for
Pancreas-Cancer Patients
C. Stein-Thoeringer

10:40 Coffee break

11:00 - 12:30 Extended coffee break
with the option to attend a
satellite symposium by GILEAD

12:30 Lunch break

ADVANCING CELLULAR IMMUNOTHERAPY

Chairs: M. Schmitt / P. Dreger

13:30 Transplantation of CD33-Depleted
Hematopoietic Stem Cells to
Broaden the Therapeutic Window
of CD33-Directed Immunotherapy
for AML
T. Sauer

13:50 CAR T-Cells in Autoimmune
Fibrotic Disease
J. Henes

14:10 CD70.CARTs against Glioblastoma
T. Kessler

14:30 CellCLIPS — Envisioning a
Professional Trial Environment,
Dedicated to Cell and Gene Therapy
Antje Blank / P. Dreger

14:50-15:00 Closing Remarks
M. Schmitt / P. Dreger